NO944764L - Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter - Google Patents
Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåterInfo
- Publication number
- NO944764L NO944764L NO944764A NO944764A NO944764L NO 944764 L NO944764 L NO 944764L NO 944764 A NO944764 A NO 944764A NO 944764 A NO944764 A NO 944764A NO 944764 L NO944764 L NO 944764L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- inclusion complexes
- water
- aqueous solutions
- pharmaceutical formulations
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Det blir fremskaffet Inklusjosnkomplekser l vandig oppløsning av visse kjente benzotiofenforbindelser, spesielt Raloxlfen, og vannoppløselige cyklodekstriner. Det blir også fremskaffet farmasøytiske sammensetninger av silke Inklusjonskomplekser og fremgangsmåter for anvendelse av disse kompleksene, for hemming av bentap og redusering av serumkolesterol hos pattedyr.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16678893A | 1993-12-14 | 1993-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO944764D0 NO944764D0 (no) | 1994-12-08 |
NO944764L true NO944764L (no) | 1995-06-15 |
Family
ID=22604709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO944764A NO944764L (no) | 1993-12-14 | 1994-12-08 | Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter |
Country Status (27)
Country | Link |
---|---|
US (1) | US5624940A (no) |
EP (1) | EP0658348B1 (no) |
JP (1) | JPH07196495A (no) |
KR (1) | KR950017949A (no) |
CN (1) | CN1109751A (no) |
AT (1) | ATE205726T1 (no) |
AU (1) | AU689817B2 (no) |
BR (1) | BR9404936A (no) |
CA (1) | CA2137533A1 (no) |
CO (1) | CO4340621A1 (no) |
CZ (1) | CZ306394A3 (no) |
DE (1) | DE69428334T2 (no) |
DK (1) | DK0658348T3 (no) |
ES (1) | ES2160615T3 (no) |
FI (1) | FI945839A (no) |
HU (1) | HUT72298A (no) |
IL (1) | IL111930A0 (no) |
NO (1) | NO944764L (no) |
NZ (1) | NZ270077A (no) |
PE (1) | PE36795A1 (no) |
PH (1) | PH31265A (no) |
PL (1) | PL306173A1 (no) |
PT (1) | PT658348E (no) |
RU (1) | RU2135176C1 (no) |
SI (1) | SI0658348T1 (no) |
YU (1) | YU72594A (no) |
ZA (1) | ZA949715B (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
USRE39049E1 (en) | 1992-07-28 | 2006-03-28 | Eli Lilly And Company | Methods for inhibiting bone loss |
USRE38968E1 (en) | 1992-07-28 | 2006-02-07 | Eli Lilly And Company | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
US6180075B1 (en) | 1997-04-09 | 2001-01-30 | Degussa-H{umlaut over (u)}ls Aktiengesellschaft | Exhaust gas catalyst |
SE9702680D0 (sv) * | 1997-07-11 | 1997-07-11 | Astra Pharma Prod | New formulation |
US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
US6566556B2 (en) * | 2000-12-19 | 2003-05-20 | Nippon Shokubai Co., Ltd. | Method for production of alkanolamine and apparatus therefor |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
US20030232068A1 (en) * | 2002-06-14 | 2003-12-18 | Lewandowski Daniel J. | Food product having increased bile acid binding capacity |
US20040157096A1 (en) * | 2002-10-07 | 2004-08-12 | Peterson Richard B. | Plug-compatible modular thermal management packages |
US20040116382A1 (en) * | 2002-12-13 | 2004-06-17 | Plank David W. | Food products containing cyclodextrins having beneficial hypocholesterolemic effects and method of making and communicating the benefit of such products |
US7105195B2 (en) * | 2003-07-25 | 2006-09-12 | General Mills, Inc. | Reduced trans fat product |
US20040180125A1 (en) * | 2003-03-11 | 2004-09-16 | Plank David W. | Cyclodextrin-containing compositions and methods |
US7335386B2 (en) * | 2003-07-30 | 2008-02-26 | Gerneral Mills, Inc. | Method for preventing acrylamide formation in food products and food intermediates |
US20060111318A1 (en) * | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
JP4564920B2 (ja) * | 2003-04-18 | 2010-10-20 | 株式会社最先端医学研究所 | 眼に適用する疾患治療剤 |
US20060106010A1 (en) * | 2003-05-27 | 2006-05-18 | Black Larry J | Methods for inhibiting bone loss |
TWI350751B (en) | 2003-12-19 | 2011-10-21 | Omega Bio Pharma Ip3 Ltd | Pharmaceutical compositions for treating diabetes |
US20060019938A1 (en) * | 2003-12-31 | 2006-01-26 | Beer Tomasz M | Estrogen administration for treating male cognitive dysfunction or improving male cognitive function |
EP2132173B1 (en) * | 2007-02-26 | 2015-10-07 | Merck Sharp & Dohme Corp. | Formulations for cathepsin k inhibitors |
EP2253627A1 (en) * | 2009-05-21 | 2010-11-24 | ERREGIERRE S.p.A. | Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin. |
CN102198274B (zh) * | 2011-03-30 | 2013-04-24 | 天津红日药业股份有限公司 | 雷洛昔芬的环糊精包合物及其制剂的制备方法 |
ITMI20121821A1 (it) * | 2012-10-25 | 2014-04-26 | Erregierre Spa | Composizione farmaceutica solubile in acqua a base di un sale di raloxifene |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
HU181703B (en) * | 1980-05-09 | 1983-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
HU199444B (en) * | 1985-09-10 | 1990-02-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
GB8813682D0 (en) * | 1988-06-09 | 1988-07-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
GB8814725D0 (en) * | 1988-06-21 | 1988-07-27 | Glaxo Group Ltd | Medicaments |
NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
US5229370A (en) * | 1988-08-15 | 1993-07-20 | Ammeraal Robert N | Water soluble branched beta cyclodextrin steroid complex |
JPH02279631A (ja) * | 1989-04-18 | 1990-11-15 | Yamanouchi Pharmaceut Co Ltd | 薬物のシクロデキストリン包接体及びその製造法 |
JPH02300140A (ja) * | 1989-05-12 | 1990-12-12 | Yamanouchi Pharmaceut Co Ltd | 薬物のシクロデキストリン包接体及びその製造法 |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5101065A (en) * | 1991-02-04 | 1992-03-31 | Imperial Chemical Industries Plc | Acetophenone intermediates |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
-
1994
- 1994-12-06 RU RU94042935A patent/RU2135176C1/ru active
- 1994-12-06 PE PE1994256569A patent/PE36795A1/es not_active Application Discontinuation
- 1994-12-06 ZA ZA949715A patent/ZA949715B/xx unknown
- 1994-12-06 CZ CZ943063A patent/CZ306394A3/cs unknown
- 1994-12-06 NZ NZ270077A patent/NZ270077A/en unknown
- 1994-12-07 CO CO94055632A patent/CO4340621A1/es unknown
- 1994-12-07 CA CA002137533A patent/CA2137533A1/en not_active Abandoned
- 1994-12-08 IL IL11193094A patent/IL111930A0/xx not_active IP Right Cessation
- 1994-12-08 NO NO944764A patent/NO944764L/no unknown
- 1994-12-08 AU AU80335/94A patent/AU689817B2/en not_active Ceased
- 1994-12-08 PL PL94306173A patent/PL306173A1/xx unknown
- 1994-12-09 DE DE69428334T patent/DE69428334T2/de not_active Expired - Fee Related
- 1994-12-09 SI SI9430398T patent/SI0658348T1/xx unknown
- 1994-12-09 EP EP94309228A patent/EP0658348B1/en not_active Expired - Lifetime
- 1994-12-09 PH PH49524A patent/PH31265A/en unknown
- 1994-12-09 DK DK94309228T patent/DK0658348T3/da active
- 1994-12-09 PT PT94309228T patent/PT658348E/pt unknown
- 1994-12-09 AT AT94309228T patent/ATE205726T1/de not_active IP Right Cessation
- 1994-12-09 ES ES94309228T patent/ES2160615T3/es not_active Expired - Lifetime
- 1994-12-10 KR KR1019940033592A patent/KR950017949A/ko not_active Application Discontinuation
- 1994-12-12 BR BR9404936A patent/BR9404936A/pt not_active Application Discontinuation
- 1994-12-12 YU YU72594A patent/YU72594A/sh unknown
- 1994-12-12 FI FI945839A patent/FI945839A/fi unknown
- 1994-12-12 JP JP6307505A patent/JPH07196495A/ja active Pending
- 1994-12-12 HU HU9403567A patent/HUT72298A/hu unknown
- 1994-12-12 CN CN94119313A patent/CN1109751A/zh active Pending
-
1995
- 1995-06-30 US US08/497,327 patent/US5624940A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2160615T3 (es) | 2001-11-16 |
HUT72298A (en) | 1996-04-29 |
JPH07196495A (ja) | 1995-08-01 |
NO944764D0 (no) | 1994-12-08 |
EP0658348B1 (en) | 2001-09-19 |
DE69428334T2 (de) | 2002-06-20 |
FI945839A (fi) | 1995-06-15 |
SI0658348T1 (en) | 2002-06-30 |
YU72594A (sh) | 1997-07-31 |
FI945839A0 (fi) | 1994-12-12 |
ZA949715B (en) | 1996-06-06 |
CN1109751A (zh) | 1995-10-11 |
AU8033594A (en) | 1995-06-22 |
NZ270077A (en) | 1996-04-26 |
PL306173A1 (en) | 1995-06-26 |
EP0658348A3 (en) | 1996-08-07 |
CO4340621A1 (es) | 1996-07-30 |
ATE205726T1 (de) | 2001-10-15 |
CA2137533A1 (en) | 1995-06-15 |
HU9403567D0 (en) | 1995-02-28 |
DE69428334D1 (de) | 2001-10-25 |
RU94042935A (ru) | 1997-01-10 |
PT658348E (pt) | 2002-02-28 |
PE36795A1 (es) | 1995-11-06 |
KR950017949A (ko) | 1995-07-22 |
IL111930A0 (en) | 1995-03-15 |
CZ306394A3 (en) | 1995-08-16 |
AU689817B2 (en) | 1998-04-09 |
EP0658348A2 (en) | 1995-06-21 |
BR9404936A (pt) | 1995-08-08 |
PH31265A (en) | 1998-06-18 |
RU2135176C1 (ru) | 1999-08-27 |
DK0658348T3 (da) | 2001-11-12 |
US5624940A (en) | 1997-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO944764D0 (no) | Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter | |
BR9811099A (pt) | Inibidores de urocinase | |
BE2015C026I2 (en) | 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens | |
TR200200068T2 (tr) | Nematisital triflüorobütenler | |
ATE225341T1 (de) | In 6-position durch thio substituierte paclitaxele | |
EP0911039A3 (en) | Drug-resin complexes stabilized by chelating agents | |
IL129592A0 (en) | 5-HT1f agonists | |
MXPA03001463A (es) | Derivados de benzofurano o benzotiofeno de aminoalquilbenzoil, metodo para preparar los mismos y composiciones que los contienen. | |
MXPA03001536A (es) | (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen. | |
MX9704034A (es) | Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso. | |
NO954442D0 (no) | Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling | |
BG107553A (en) | Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same | |
ZA981558B (en) | Inclusion complexes in aqueous solution | |
NZ505085A (en) | Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi |